# **ALAPIS**

**ALAPIS S.A.** 

**Greece, Health, Pharmaceuticals** 

## **November 26, 2008**

## **Company Description**

Alapis Group is primarily active in 2 major strategic business units:

I. Healthcare: Pharmaceuticals, Medical Devices & Equipment,

Veterinary Pharmaceuticals and

II. Non-Healthcare: Detergents &

Cosmetics, and Organic Products.

## **Share Data**

Price (€) 25/11/2008	1.08
# of shares (M.)	980.6
Capitalization (M €)	1,059
ATHEX	ALAPIS
REUTERS	ALAr.AT
BLOOMBERG	ALAPIS_GA
ISIN	GRS 322003013

## **Pro Forma Figures**

P&L HIGHLIO	GHTS	FY 2005	FY 2006	FY 2007
SALES	(000 €)	180,120	273,456	472,746
EBITDA	(000 €)	25,847	46,107	123,644
EATAM	(000 €)	-9,399	20,095	87,465
RATIOS		FY 2005	FY 2006	FY 2007
P/E	(x)	-112.68	52.70	12.11
P/BV	(x)	6.12	1.43	0.66
EV/EBITDA	(x)	44.50	25.38	6.73

Investment ratios computed at share price 1.08 (24/11/2008) and no. of shares 980,600,220.

The above results are not comparable with the equivalent results of the respective period of 2006, as they do not include the absorbed companies.

## **Key Developments**

In 9M 2008, ALAPIS Group of Companies turnover amounted to EUR 702 mil., significantly increased by 215.1% over 9M 2007, while consolidated EBITDA stood at EUR 190.7 mil. increased by 185.0% and earnings after tax and minorities reported at EUR 103.8 mil. up by 138.0% over the respective period last year.

9M 2008 results have been affected by the significant performance of the healthcare division because of both the consolidation of all acquired companies and the benefits from the vertical integration of this sector's activities. It should also be note that the activity slowdown of the non-health care division (detergents and organic products) is due to the global credit crisis.

## **Healthcare division**

**Healthcare division (human and Veterinary)** turnover amounted to EUR 547.8 mil. while EBITDA stood at EUR 156.4 mil.

### Non-healthcare division

Non-healthcare division (Detergents - Cosmetics and Organic products) turnover totaled EUR 154.2 mil. while EBITDA reached EUR 34.3 mil.

#### **Financial Guidance for 2008**

**FY 2008(e)**: Turnover: EUR 900-1,000 mil., EBITDA EUR 250-270 mil. and earnings after tax and minority rights approximately EUR 160 mil.

## **9M Financial Results**


(FY: December) (M €)	9M 2007	9М 2008	Δ (%)
Sales	222,8	702,0	215,1%
Gross Profit	91,2	227,6	149,4%
EBITDA	66,9	190,7	185,0%
EBIT	54,4	143,9	164,3%
EBT	48,9	129,2	164,3%
EAT & Minorities	43,6	103,8	138,0%
Margin Analysis %	9M 2007	9M 2008	
Gross Profit	41,0%	32,4%	
EBITDA	30,0%	27,2%	
EBIT	24,4%	20,5%	
EBT	21,9%	18,4%	
EAT & Minorities	19,6%	14,8%	


Reclassifications have been made in 2007 figures due to the finalization of the goodwill of the merger


156.4 82.0%

Healthcare

Consc	olidate	d Inc	ome	State	eme	nt		
(FY: December) (000 €)	Q1 2007	Q2 2007	Q3 2007	9M 2007	Q1 2008	Q2 2008	Q3 2008	9M 2008
Sales	49.511	83.728	89.551	222.791	208.091	256.302	237.596	701.989
Cost of Goods Sold	-31.301	-48.765	-51.484	-131.550	-143.371	-175.766	-155.288	-474.425
Gross Profit	18.210	34.963	38.067	91.241	64.720	80.536	82.308	227.564
Other Revenues-(Expenses)	472	340	510	1.322	3.561	-2.571	864	1.855
SG&A Expenses	-8.169	-14.396	-15.550	-38.114	-25.186	-24.279	-36.061	-85.526
EBITDA	12.523	26.747	27.651	66.922	57.603	68.423	64.691	190.716
Depreciation	-2.009	-5.840	-4.624	-12.473	-14.508	-14.736	-17.580	-46.823
EBIT	10.514	20.907	23.027	54.449	43.095	53.687	47.111	143.893
Total Financial Results	-1.194	-2.307	-2.059	-5.560	-2.694	-3.831	-8.169	-14.694
ЕВТ	9.319	18.600	20.968	48.889	40.401	49.856	38.942	129.199
Taxation	-1.920	-2.904	-462	-5.287	-7.140	-12.365	-6.144	-25.649
Minorities	0	0	0	0	-54	-126	-42	-22
EAT & Minorities	7.399	15.696	20.506	43.602	33.314	37.617	32.840	103.77
Margin Analysis %	Q1 2007	Q2 2007	Q3 2007	9M 2007	Q1 2008	Q2 2008	Q3 2008	9M 2008
Gross Profit	36,8%	41,8%	42,5%	41,0%	31,1%	31,4%	34,6%	32,4%
SG&A Expenses	16,5%	17,2%	17,4%	17,1%	12,1%	9,5%	15,2%	12,2%
	25,3%	31,9%	30,9%	30,0%	27,7%	26,7%	27 20/	27,2%
EBITDA	25,570	31,570	30,570			20,7 70	27,2%	
	21,2%	25,0%	25,7%	24,4%	20,7%	20,9%	19,8%	
EBIT								20,5%
EBIT	21,2%	25,0%	25,7%	24,4%	20,7%	20,9%	19,8%	20,5% 18,4%
EBIT EBT EAT & Minorities	21,2% 18,8%	25,0% 22,2%	25,7% 23,4%	24,4% 21,9%	20,7% 19,4%	20,9% 19,5%	19,8% 16,4%	20,5% 18,4% 14,8%
EBIT EBT EAT & Minorities Period / Period %	21,2% 18,8% 14,9%	25,0% 22,2% 18,7%	25,7% 23,4% 22,9%	24,4% 21,9% 19,6%	20,7% 19,4% 16,0%	20,9% 19,5% 14,7%	19,8% 16,4% 13,8%	20,5% 18,4% 14,8%
EBIT EBT EAT & Minorities Period / Period % Sales	21,2% 18,8% 14,9%	25,0% 22,2% 18,7% <b>Q2 2007</b>	25,7% 23,4% 22,9% <b>Q3 2007</b>	24,4% 21,9% 19,6% <b>9M 2007</b>	20,7% 19,4% 16,0% <b>Q1 2008</b>	20,9% 19,5% 14,7% <b>Q2 2008</b>	19,8% 16,4% 13,8% Q3 2008	20,5% 18,4% 14,8% <b>9M 200</b> 8
EBIT EBT EAT & Minorities Period / Period % Sales Gross Profit	21,2% 18,8% 14,9%	25,0% 22,2% 18,7% <b>Q2 2007</b> 656,4%	25,7% 23,4% 22,9% <b>Q3 2007</b> 748,0%	24,4% 21,9% 19,6% <b>9M 2007</b> 593,5%	20,7% 19,4% 16,0% <b>Q1 2008</b> 320,3%	20,9% 19,5% 14,7% <b>Q2 2008</b> 206,1%	19,8% 16,4% 13,8% <b>Q3 2008</b> 165,3%	20,5% 18,4% 14,8% <b>9M 2008</b> 215,1%
EBIT EBT EAT & Minorities Period / Period % Sales Gross Profit SG&A Expenses	21,2% 18,8% 14,9%	25,0% 22,2% 18,7% <b>Q2 2007</b> 656,4% 897,8%	25,7% 23,4% 22,9% <b>Q3 2007</b> 748,0% 1335,9%	24,4% 21,9% 19,6% <b>9M 2007</b> 593,5% 841,2%	20,7% 19,4% 16,0% <b>Q1 2008</b> 320,3% 255,4%	20,9% 19,5% 14,7% <b>Q2 2008</b> 206,1% 130,3%	19,8% 16,4% 13,8% <b>Q3 2008</b> 165,3% 116,2%	20,5% 18,4% 14,8% <b>9M 2008</b> 215,1% 149,4%
EBIT EBT EAT & Minorities Period / Period % Sales Gross Profit SG&A Expenses EBITDA	21,2% 18,8% 14,9%	25,0% 22,2% 18,7% <b>Q2 2007</b> 656,4% 897,8% 431,8%	25,7% 23,4% 22,9% <b>Q3 2007</b> 748,0% 1335,9% 593,0%	24,4% 21,9% 19,6% <b>9M 2007</b> 593,5% 841,2% 373,6%	20,7% 19,4% 16,0% <b>Q1 2008</b> 320,3% 255,4% 208,3%	20,9% 19,5% 14,7% <b>Q2 2008</b> 206,1% 130,3% 68,6%	19,8% 16,4% 13,8% <b>Q3 2008</b> 165,3% 116,2% 131,9%	20,5% 18,4% 14,8% 9M 2008 215,1% 149,4% 124,4%
EBIT EBT EAT & Minorities Period / Period % Sales Gross Profit SG&A Expenses EBITDA	21,2% 18,8% 14,9%	25,0% 22,2% 18,7% <b>Q2 2007</b> 656,4% 897,8% 431,8% 1338,0% 1357,9%	25,7% 23,4% 22,9% <b>Q3 2007</b> 748,0% 1335,9% 593,0% 3767,3%	24,4% 21,9% 19,6% 9M 2007 593,5% 841,2% 373,6% 1753,8%	20,7% 19,4% 16,0%  Q1 2008 320,3% 255,4% 208,3% 360,0%	20,9% 19,5% 14,7% <b>Q2 2008</b> 206,1% 130,3% 68,6% 155,8%	19,8% 16,4% 13,8%  Q3 2008 165,3% 116,2% 131,9% 134,0%	20,5% 18,4% 14,8% <b>9M 2008</b> 215,1% 149,4% 124,4% 185,0%
EBITDA EBIT EBT EAT & Minorities  Period / Period %  Sales Gross Profit SG&A Expenses EBITDA EBIT EBT EAT & Minorities	21,2% 18,8% 14,9%	25,0% 22,2% 18,7% <b>Q2 2007</b> 656,4% 897,8% 431,8% 1338,0% 1357,9% 10291,1%	25,7% 23,4% 22,9% <b>Q3 2007</b> 748,0% 1335,9% 593,0% 3767,3% 5789,3% 11484,5%	24,4% 21,9% 19,6% 9M 2007 593,5% 841,2% 373,6% 1753,8% 2312,5% 4976,7%	20,7% 19,4% 16,0%  Q1 2008 320,3% 255,4% 208,3% 360,0% 309,9%	20,9% 19,5% 14,7% <b>Q2 2008</b> 206,1% 130,3% 68,6% 155,8%	19,8% 16,4% 13,8%  Q3 2008 165,3% 116,2% 131,9% 134,0% 104,6%	9







This presentation contain forward-looking statements. These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Group. They are not historical facts, nor are they guarantees of future performance. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Further details of potential risks and uncertainties affecting ALAPIS Group are described in the ALAPIS's filings with the Athens Stock Exchange. These forward-looking statements speak only as of the date of this presentation.